Featured

Dyne Therapeutics' DYNE-251 Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy

Dyne Therapeutics announced that the FDA granted Breakthrough Therapy Designation to DYNE-251 for treating Duchenne muscular dystrophy (DMD) amenable ...

Home/KnolSights/Regulatory Approvals/Dyne Therapeutics' DYNE-251 Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy